OSTEOPORE LIMITED — Capital/Financing Update 2023

Apr 10, 2023

==> picture [145 x 59] intentionally omitted <==

ASX RELEASE | OSTEOPORE LIMITED

OSTEOPORE STRENGTHENS PRESENCE IN THE EASTERN REGION OF THE UNITED STATES

Highlights:

• Osteopore announces a strategic sub-distribution partnership with Kelyniam through its U.S. sales distribution partner, Bioplate Inc. to further penetrate the USD1.1 billion cranial implant market.

• Kelyniam specialises in custom prosthetics production using computer-aided design and manufacturing of advanced medical grade polymers, and has 60 sales representatives covering the Eastern region.

• Kelyniam will focus on securing sales in approximately 20 hospitals across 8 states. Prestigious institutions targeted include John Hopkins Hospital, Boston Medical Center and Tampa General Hospital.

• Osteopore products have FDA clearance and are available in the U.S. The Company believes that it is now poised to enhance market penetration and contribute to future growth, especially with product average selling price up to five times higher as compared to countries in ASEAN and Asia Pacific.

11 April 2023: Osteopore Limited (ASX: OSX) (“Osteopore” or the “Company”), a global leader in the manufacture of innovative regenerative implants that empower natural tissue regeneration, is pleased to announce its U.S. sales distribution partner, Bioplate Inc., has entered into a strategic sub-distribution partnership with Kelyniam.

Kelyniam specialises in the rapid production of custom prosthetics utilising computer aided design and computer aided manufacturing of advanced medical grade polymers. They have established themselves as an esteemed distributor within the U.S. medical industry, making them a valuable partner in our ongoing expansion efforts.

Osteopore products are already available for sale in the U.S. and have U.S. Food and Drug Administration (FDA) clearance. Kelyniam's primary focus initially, will be to secure sales for Osteopore products in a targeted set of approximately 20 hospitals across 8 key states, granting surgeons enhanced access to our bone regeneration technology. Among the prestigious institutions selected for this initiative are Johns Hopkins Hospital, Boston Medical Center and Tampa General Hospital.

Osteopore Limited (ACN 630 538 957)│ASX:OSX│16 Ord Street, West Perth│+618 9482 0500│www.osteopore.com

==> picture [145 x 59] intentionally omitted <==

With an addressable market of USD1.1 billion[1] (Compound Annual Growth Rate (CAGR) of 6.4% from 2022 to 2030[2] ), the U.S. cranial implant market is a significant opportunity for Osteopore. This latest sub-distribution partnership means that Osteopore has achieved substantial coverage of the U.S. In addition to Bioplate‘s network, the Company will be able to leverage Kelyniam’s sales force of 60 representatives to further penetrate the market. The Company believes that it is now equipped with the resources and channels to meaningfully operate in the U.S. The pricing structure in the U.S. has the potential to improve top line revenue with product average selling prices between three to five times higher compared to countries in ASEAN and Asia Pacific.

Osteopore’s Executive Chairman, Mark Leong said: “ We are excited to work closely with Kelyniam and Bioplate to achieve our shared goals and contribute to the ongoing advancement of patient care and improved surgical outcomes. Their industry knowledge and dedication to excellence make them the perfect partner to help us expand our reach and impact in the North-East United States. "

CEO of Kelyniam Global, Ross Bjella said: “ Kelyniam continues to seek collaboration with technology leading companies in cranial surgery. The Osteopore technology will allow our sales representatives to bring this regenerative platform to surgeons who look to Kelyniam for innovative products. The Osteopore relationship provides Kelyniam the opportunity to further expand our position in the U.S. market. We are excited to support the adoption of this totally new technology in selected hospitals across several states. ”

President of Bioplate, Thomas Hopson said: “ With the expansion of Bioplate’s commercial team, we are building a stronger position to expand Osteopore’s penetration in the U.S. market. This new team will allow us to further support marketing activities and sales network across more states. Today we have hospital accounts with products on the shelf in Texas, Nebraska and Idaho, and recently approved in a key institution in southern California. Our team continue to work on listing Osteopore implants in selected hospitals across 13 states. Kelyniam has been part of Bioplate’s distribution network for its legacy products and will be able to leverage on Kelyniam’s strong customer base in north-eastern U.S. and Florida. ”

Additional Agreement Details

This Agreement signed between Bioplate and Kelyniam effective March 30, 2023, shall be for a term of 36 months (“Initial Term”) and may be renewed for a successive term(s) as agreed to by the parties. The terms of the Agreement do not contain binding minimum sales thresholds. Each party will bear their own costs. Either party may terminate the Agreement as of the end of the Initial Term or any additional term by providing 30 days written notice thereof to the other party. The Agreement also contains such other terms that are standard in commercial distribution agreements of this type.

1 CETAS Healthcare commissioned market research report, January 2021.

2 https://www.globenewswire.com/news-release/2023/02/23/2614470/0/en/Cranial-Implants-Market-SizeGrowing-at-6-4-CAGR-Set-to-Reach-USD-2-058-Million-By-2030.html

Osteopore Limited (ACN 630 538 957)│ASX:OSX│16 Ord Street, West Perth│+618 9482 0500│www.osteopore.com

==> picture [145 x 59] intentionally omitted <==

This announcement has been approved for release by the Board of Osteopore.

For more information, please contact:

Mark Leong

Executive Chairman Osteopore Limited +65 9011 7009 Mark_Leong@osteopore.com

About Osteopore Limited

Osteopore Ltd is an Australia and Singapore based medical technology company commercialising a range of products specifically engineered to facilitate natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific microstructured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing post-surgery complications commonly associated with permanent bone implants. Our 3D printer technology is not available in the market and unique to Osteopore.

About Kelyniam

Kelyniam Inc., specialises in the rapid production of custom prosthetics utilising computer aided design and computer aided manufacturing of advanced medical grade polymers. The company develops, manufactures, and distributes custom cranial and maxillo-facial implants for patients. Kelyniam works directly with surgeons, health systems and payors to improve clinical and cost-of-care outcomes.

About Bioplate

Bioplate designs and manufactures a range of cranial closure products for neurosurgical procedures. Founded in 1995, the company’s mission is to deliver high-quality, innovative products that help patients requiring neurosurgery. Its current portfolio of products includes titanium plates and screws, bioresorbable bone scaffolds, and patient-matched PEEK craniofacial plates. In addition, the company specialises in providing contract manufacturing services for companies in the orthopedic segment. Bioplate is a privately held corporation based in Orange County, California.

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are, or may be, forward-looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and

Osteopore Limited (ACN 630 538 957)│ASX:OSX│16 Ord Street, West Perth│+618 9482 0500│www.osteopore.com

==> picture [145 x 59] intentionally omitted <==

uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on various factors.

Osteopore Limited (ACN 630 538 957)│ASX:OSX│16 Ord Street, West Perth│+618 9482 0500│www.osteopore.com